生物工程微RNA-7有效地干扰了Akt3 / p53轴,以抑制人类非小细胞肺癌
Qian Huang1, Xiaohua Chu1, Chaofei Yang2
1Lab for Bone Metabolism, Xi'an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an, 710072, Shaanxi, China.
Cancer cell international
|July 3, 2025
概括
生物工程微RNA-7 (miR-7) 有效抑制非小细胞肺癌 (NSCLC) 的生长和转移. 这种新疗法针对Akt3,与p53通路相互作用以抑制瘤发展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因,有效治疗方法有限.
- 瘤抑制蛋白p53在NSCLC中起着至关重要的作用,而microRNAs (miRs) 可以调节其功能.
- 确定NSCLC的新型治疗点和策略至关重要.
研究的目的:
- 研究不同表达的microRNAs (miRs) 在NSCLC中的作用,重点研究miR-7.
- 开发和评估生物工程miR-7对NSCLC的治疗潜力.
- 阐明miR-7在NSCLC中的作用机制,包括它与p53和新标的相互作用.
主要方法:
- 生物信息分析以选p53相关的miRs,在NSCLC中差异表达.
- 开发一种新的混合tRNA支架,用于生物工程miR-7生产.
- 试验室试验评估miR-7对NSCLC细胞增殖,迁移,入侵和亡的影响.
- 在体内研究中,使用正体NSCLC异种移植小鼠模型来评估瘤生长抑制.
- 识别新型miR-7点,并研究其与p53通路的相互作用.
主要成果:
- 过度表达miR-7显著抑制NSCLC细胞的增殖,迁移和入侵,同时诱导细胞亡.
- 生物工程miR-7在体内NSCLC小鼠模型中显著抑制了瘤生长.
- 鉴定出Akt3是miR-7的一个新型直接标.
- miR-7通过抑制Akt抑制瘤生长并使NSCLC细胞对化疗敏感,这反过来减少了MDM2-介导的p53降解.
结论:
- miR-7,特别是其生物工程形式,对NSCLC表现出显著的抗瘤活性.
- miR-7针对Akt3并与p53通路相互作用以抑制NSCLC的发展.
- 生物工程miR-7具有治疗非小细胞肺癌的治疗潜力.
相关概念视频
MicroRNAs
21.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K


